Hidden health benefits from weight-loss shots revealed
The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death.
Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood.
The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity.
Roughly half of the participants were given GLP agonist drugs.
These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required.
The other half used other anti-diabetic medication.
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke.
Weight-loss drugs like Wegovy are available on the NHS to obese patients
They were also 30 per cent less likely to die during the follow-up period.
When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
GLP-1 drugs increase risk of acid reflux, GERD, study finds
July 14 (UPI) -- Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD) if they were prescribed a GLP-1 drug compared to those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors, researchers reported Tuesday in the Annals of Internal Medicine. "We estimated that most GLP-1 [drugs] increased risk for GERD," concluded the research team led by Laurent Azoulay, an associate professor with the Jewish General Hospital's Center for Clinical Epidemiology in Montreal, Canada. The risk for serious GERD-related complications was higher among smokers, people with obesity and folks with existing stomach problems, researchers said. "Although our findings need to be corroborated in other studies, clinicians and patients should be aware of a possible adverse effect of GLP-1 [drugs] on GERD," researchers noted. For the study, researchers tracked more than 24,700 type 2 diabetics newly prescribed GLP-1 drugs, comparing their health to that of more than 89,000 who were prescribed SGLT-2 inhibitors. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Because the drugs slow the rate at which food passes through the stomach, researchers thought they might increase the risk of acid reflux. GERD occurs when acid reflux happens repeatedly over time, the Mayo Clinic says. If it continues, GERD can cause scarring and narrowing of the esophagus and increase a person's risk of esophageal cancer. Results show that people taking GLP-1 drugs were 27% more likely to develop GERD and 55% more likely to have GERD complications, when compared to people taking SGLT-2 inhibitors. More than 90% of GERD complications involved Barrett esophagus, in which acid damage changes the tissue lining of the esophagus and increases cancer risk, researchers noted. "We also found that the risk for GERD was higher with long-acting GLP-1 (drug) use," researchers wrote. However, they noted that these findings need to be verified by studies involving other groups, including those taking GLP-1 drugs for obesity. "There is limited evidence on the risk for GERD among patients with obesity who do not have type 2 diabetes," researchers wrote. "Use of GLP-1 [drugs] is rapidly expanding in this population, highlighting an important area for future research." More information The Mayo Clinic has more on GERD. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
4 hours ago
- Yahoo
Sugar, sex and your health: The connection you might be ignoring
Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida's College of Medicine. When most of us think about sugar, I bet we're not thinking about our sex lives. We're thinking about dessert. I'm writing this with the help of a bowl of vanilla ice cream by my side. Sugar makes us feel good in the moment, but over time, too much of it may cause us to lose out on some of life's most intimate moments. In 2025, everyone's been buzzing about GLP-1 injections to help control sugar and lose weight. This new class of medication has helped many achieve meaningful health gains — including improved blood sugar, weight loss — and even improvements to people's sex lives (because they could be getting better sleep, too). My goal here isn't to discount the use of GLP-1 drugs or suggest people are taking them unnecessarily (although some people may be). My intent is to spark a broader conversation: What if we also paid more attention to the root cause: our love for sugar and its downstream effects on mood, metabolism, sex and more? Most people associate blood sugar with diabetes, but few know what is 'normal.' Blood sugar levels can be checked in real time with a simple finger stick, via home glucose monitor or through wearable devices such as continuous glucose monitors (those coin-size devices you may see on people's upper arms), which provide feedback on glucose levels throughout the day. What do we see when this test is done? Following is the American Diabetes Association range of reference for blood glucose levels, but they are not meant for you to diagnose yourself with diabetes. In many instances, your provider may double- or even triple-check these numbers before labeling you with 'diabetes.' All numbers should be evaluated by your health care provider. Fasting blood sugar (no food for at least eight hours prior): Normal: below 100 mg/dL (milligrams per deciliter) Prediabetes: 100 to 125 mg/dL Diabetes: 126 mg/dL or higher Random blood sugar (taken any time of day): Diabetes is often diagnosed if levels are 200 mg/dL or higher with symptoms. The point-of-care glucose test gives a snapshot, but there's one lab that tells the full story — the hemoglobin A1c. This blood test measures the percentage of hemoglobin proteins in your blood that have glucose attached to it — giving you and your health care providers a picture of your average blood sugar over the past two to three months. This makes it a reliable indicator of how well your body manages glucose over time. Here's how the American Diabetes Association breaks it down: Normal: A1c below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or higher In my work as a surgeon, checking A1c before any procedure — especially those involving implants — is standard practice. Elevated A1c levels are strongly linked to poor recovery, infection risks and surgical complications. So, whether it's a major urologic procedure or something else, keeping your glucose in check matters more than most people realize. Sexual health is rarely the first thing people associate with blood sugar, but chronically high glucose levels can have an impact on intimacy — for everyone. In men, high blood sugar can damage the nerves and blood vessels essential for achieving and maintaining erections. Over time, this can present as erectile dysfunction, before a man is ever diagnosed with or thought to be at risk for diabetes. High blood sugar can also lower testosterone levels, which then reduce libido and energy. Many of my patients who do not get routine screenings from their primary care providers come to see me because of changes in sexual performance — only to later discover their blood sugar is out of control. For these patients, their first clue that something was wrong wasn't thirst, weight changes or fatigue (the more common early signs of diabetes) — it was trouble in the bedroom. In women, high blood sugar can lead to reduced blood flow and hormone imbalances, which may cause vaginal dryness, painful sex or problems with orgasm. It can also increase the risk of recurrent urinary tract infections, which can make intimacy painful or less appealing. Many women can feel frustrated and confused about whether these changes are expected from aging, post-menopause, stress or something else. A poor sugar level is usually the last thing on their mind. Diabetes is incredibly common — about 38 million Americans have it — and nearly 1 in 4 don't even know it, according to the US Centers for Disease Control and Prevention. Traditionally, diabetes treatment started with oral medications like metformin, which helps lower glucose by reducing sugar production in the liver. Other classes of pills work in different ways, either by increasing insulin release or helping the kidneys flush out excess sugar. These medications are typically prescribed for people in the earlier stages of diabetes or with mildly elevated A1c. Injectable medications may be necessary when oral pills aren't enough to treat the disease. For years, that often meant daily insulin injections, which many patients found to be burdensome but necessary. Insulin needs to be carefully timed with meals, and dosing can be tricky. There's also a real fear of low blood sugar episodes, which can make some people hesitant to start or stick with the therapy. Over the past few years, GLP-1 receptor agonist drugs have become part of many people's treatment regimens. This class of medication is known by names like semaglutide, liraglutide and tirzepatide. These injections mimic a natural hormone in your body that helps regulate blood sugar, slows down digestion and make you feel fuller faster. While they were originally developed to treat type 2 diabetes, they've gained worldwide attention for helping people lose weight. In fact, many patients now ask and get these medications before any other option — not just to manage blood sugar, but to lose weight. These medications also may help normalize testosterone levels in men with obesity or type 2 diabetes, according to preliminary research presented at the Endocrine Society's annual meeting this week. Researchers tracked 110 men who were prescribed GLP-1 injections but were not taking any testosterone therapy. Over the course of 18 months, as participants lost on average about 10% of their body weight, the number of men with normal testosterone levels increased from 53% to 77%. This rise highlights how medications originally designed for diabetes and weight loss also may improve hormone levels in men. While this abstract has not yet been peer-reviewed and more research is needed, these findings add to a growing body of evidence that managing weight and blood sugar can have ripple effects across nearly every aspect of health — including testosterone, energy and sexual function. Before turning immediately to medications, don't underestimate what consistent lifestyle changes can do, not just for your blood sugar but for your whole life. Regular exercise improves insulin sensitivity, supports weight loss, boosts energy and even enhances sexual function by improving blood flow and hormone balance. A balanced diet — one that's rich in whole foods, fiber and lean protein — can stabilize blood sugar and reduce inflammation that contributes to chronic disease. Better sleep, reduced alcohol and managing stress all play a role, too. So, if you're debating between an injection or a new routine, maybe this time reach for the gym bag before you try anything else. You might just find it changes more than your labs. It might change how you feel about yourself. As for me, the next time I help myself to that scoop of ice cream while writing, I'll remember that it's not just about my waistline — it's about my energy, my heart and my sexual health. And now that I'm done with this article, I'll pick up my gym bag and walk the walk (to the gym) that I'm talking here. Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Yahoo
4 hours ago
- Yahoo
Physician associates ‘should be banned from seeing patients without review'
Physician associates (PAs) should be banned from seeing patients who have not been reviewed by a medic to prevent the risk of 'catastrophic' misdiagnoses, a Government-ordered report has found. The study suggests a major change to the role of PAs after it acknowledged they have been used as substitutes for doctors, despite having significantly less training. More than 3,500 PAs and 100 anaesthesia associates (AAs) are working in the NHS and there have been previous calls for an expansion in their number. But a general lack of support for the roles from the medical profession – plus high-profile deaths of patients who were misdiagnosed by PAs – led Health Secretary Wes Streeting to order a review. Presenting her findings, Professor Gillian Leng, president of the Royal Society of Medicine, said: 'Crucially I'm recommending that PAs should not see undifferentiated or untriaged patients. 'If (patients) are triaged, they (PAs) should be able to see adult patients with minor ailments in line with relevant guidance from the Royal College of GPs.' She said more detail was needed on which patients can be seen by PAs and national clinical protocols should be developed in this area. She added: 'Let's be clear, (the role of PAs) is working well in some places, but there indeed has been some substitution and any substitution is clearly risky and confusing for patients.' Prof Leng also recommended PAs should be renamed 'physician assistants' to position them 'as a supportive, complementary member of the medical team', while AAs should be renamed 'physician assistants in anaesthesia'. Newly qualified PAs should also work in hospitals for two years before they are allowed to work in GP surgeries or mental health trusts. The study said safety concerns in relation to PAs were 'almost always about making a diagnosis and deciding the initial treatment, particularly in primary care or the emergency department, where patients first present with new symptoms.' It added: 'It is here that the risk of missing an unusual disease or condition is highest, and where the more extensive training of doctors across a breadth of specialties is important. 'Making the wrong initial diagnosis and putting patients on an inappropriate pathway can be catastrophic.' Despite the shorter two years of training for PAs, where local NHS services have struggled with filling roles, 'the easy option in some cases was simply to fill gaps in medical rotas with PAs', the report went on. 'This seems to have been done without taking into account the more limited training of the PAs and how the roles would interact, other than with the caveat that they would be supervised by doctors. 'This lack of planning may have been responsible for driving the resentment felt by some resident (doctors) and potentially exposed patients to unnecessary risk.' The study noted concerns in the medical profession about the impact on training and employment of resident doctors when PAs take on tasks. When it comes to the safety of PAs and AAs, Prof Leng said the 'evidence is poor', with 'no compelling evidence' in published research 'that PAs were safe to work as doctor substitutes in primary care'. She also said the evidence was poor when it came to cost effectiveness. The report said that while research suggests patients are satisfied after seeing a PA, some did not know they were not seeing a doctor. Many doctors also told the review they were concerned about the time required to supervise PAs and AAs and the lack of training for supervisors about the role of PAs. A survey conducted for the report found 'relatively few doctors felt it was appropriate for PAs to diagnose illness', with only 29% of those working with PAs in primary care backing this, and 14% in secondary care. The survey also found 'marked differences in which tasks were considered appropriate in primary and secondary care, with PAs significantly more likely than doctors to believe that certain activities were appropriate for them to carry out'. When it came to AAs, there were also questions over whether the role was actually needed as fully qualified anaesthetists already face tough competition to find a job. Prof Leng concluded there were 'no convincing reasons to abolish the roles of AA or PA' but there is also no case 'for continuing with the roles unchanged'. She recommended that both PAs and AAs should have the opportunity for ongoing training and development, with potential to prescribe medicines in the future, and they should also should have the opportunity to become an 'advanced' PA or AA. A named doctor should take overall responsibility for each PA, while clothing, lanyards, badges and staff information should be standardised to 'distinguish physician assistants from doctors'. Six patient deaths linked to contact with PAs have been recorded by coroners in England. One high-profile death involved Emily Chesterton, 30, who died from a pulmonary embolism. She was misdiagnosed by a PA on two occasions and told she had anxiety. Unison head of health, Helga Pile, said: 'By working closely with doctors and other healthcare professionals, these roles can make a real difference to the improvement of services and reduction of waiting lists. 'Clearer identification of physician associates and anaesthesia associates will give patients a greater understanding of who's delivering their care and what they can expect. ' Dr Tom Dolphin, chair of BMA council, said the review 'laid bare the catastrophic failures in NHS leadership that have put patients at serious risk of harm' but said its recommendations 'do not adequately protect patients'. He added: 'Despite correctly recommending that assistants shouldn't be the first person seeing patients coming straight through the doors in GP practices or in A&E, the report then contradicts itself by saying that PAs can act as a first point of contact in primary care for minor and common conditions. 'It is not clear how these two recommendations can coexist, and this must be urgently clarified. Minor complaints are only minor in retrospect and serious conditions can present in subtle or unusual ways. 'No doubt doctors will look back at this report as a moment when historic failures could have been addressed and patients finally protected – but sadly will see this as an inadequate response to what is a patient safety scandal.'
